Sara Cresta
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021
25.08.2021A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
25.08.2021Clin Cancer Res 2021
Jhaveri Komal, De Vita Serena, Crystal Adam, He Wei, Ji Yan, Balbin Alejandro, Sheng Qing, Kundamal Nicole, Huober Jens, Takahashi Shunji, Terret Catherine, Duhoux Francois P, Layman Rachel M, Cresta Sara, Yap Yoon-Sim, Juric Dejan, Curigliano Giuseppe
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
20.09.2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
20.09.2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca